bovin
respiratori
diseas
brd
multifacet
diseas
involv
combin
stress
immunocompromis
viral
bacteri
pathogen
control
brd
among
newli
receiv
cattl
greatest
challeng
face
stocker
feedlot
segment
beef
cattl
product
edward
precondit
manag
practic
prepar
immatur
calv
stocker
feedlot
entri
reduc
stress
enhanc
diseas
protect
prearriv
vaccin
cole
duff
galyean
precondit
calv
improv
health
perform
compar
highrisk
calv
origin
auction
market
clark
et
al
seeger
et
al
howev
adopt
rate
manag
factor
includ
wean
respiratori
vaccin
us
beef
cowcalf
oper
remain
low
usda
bovin
viral
diarrhea
viru
bvdv
may
contribut
brd
pathogenesi
indirect
effect
immunosuppress
welsh
et
al
calv
born
persist
infect
pi
bvdv
primari
sourc
bvdv
transmiss
fulton
et
al
although
preval
pibvdv
anim
feedlot
estim
rel
low
loneragan
et
al
singl
pibvdv
anim
potenti
continu
expos
cohort
entir
pen
adjac
pen
viru
research
observ
conflict
decis
invest
pibvdv
control
program
newli
receiv
cattl
remain
controversi
one
inconsist
among
literatur
use
experiment
anim
vari
manag
health
histori
hypothes
health
perform
alter
exposur
pibvdv
pen
mate
highrisk
commingl
cohort
howev
effect
pibvdv
exposur
less
extens
singlesourc
precondit
calv
object
evalu
effect
pibvdv
exposur
determin
health
perform
outcom
differ
diverg
manag
system
total
crossbr
male
beef
calv
use
determin
effect
wean
manag
pibvdv
exposur
calv
differ
wean
manag
system
use
receiv
trial
lowrisk
singlesourc
precondit
pc
crossbr
steer
calv
n
initi
bw
kg
arriv
shipment
block
arkansa
cowcalf
ranch
highrisk
commingl
auction
market
crossbr
bull
n
steer
n
calv
initi
bw
kg
arriv
shipment
block
assembl
multipl
arkansa
auction
market
shipment
block
pc
calv
origin
cowcalf
herd
locat
izard
block
hempstead
block
pulaski
block
counti
ar
pc
calv
arriv
univers
arkansa
agricultur
experi
station
locat
near
savoy
receiv
unit
ru
octob
januari
august
decemb
respect
pc
cattl
consid
lowrisk
develop
sign
brd
wean
vaccin
brd
pathogen
shipment
maintain
singl
sourc
without
commingl
shipment
block
calv
assembl
order
buyer
public
auction
market
locat
northwest
north
central
ar
arriv
ru
octob
januari
august
decemb
shipment
block
respect
order
buyer
instruct
purchas
cattl
similar
bw
phenotyp
accompani
pc
steer
cattl
consid
highrisk
develop
sign
brd
known
health
vaccin
histori
commingl
extens
result
greater
probabl
physiolog
stress
exposur
brd
pathogen
main
effect
manag
pc
pibvdv
exposur
expos
pi
expos
con
result
treatment
arrang
factori
pc
treatment
trial
initi
depend
block
randomli
select
steer
wean
earnotch
test
pibvdv
statu
commerci
laboratori
cattl
stat
llc
oklahoma
citi
ok
use
antigencaptur
elisa
ace
method
idexx
laboratori
inc
westbrook
also
day
wean
pc
calv
administ
pentaval
modifiedl
viru
mlv
respiratori
vaccin
contain
infecti
bovin
rhinotrach
viru
bvdv
type
viru
bovin
respiratori
syncyti
viru
isol
express
boehring
ingelheim
vetmedica
inc
bivi
st
joseph
mo
manheimia
haemolyticapastuerella
multocida
bacterintoxoid
pulmoguard
bivi
pouron
inject
anthelmint
depend
block
cydectin
bivi
approxim
later
pc
calv
administ
clostridi
bacterintoxoid
alpha
bivi
revaccin
pentaval
mlv
respiratori
vaccin
precondit
phase
pc
steer
isol
cattl
ranch
fed
hay
pastur
along
supplement
remain
origin
ranch
approxim
ship
ru
upon
arriv
ru
pc
calv
held
singl
isol
unload
pen
ad
libitum
access
hay
water
trial
initi
pc
calv
weigh
return
isol
unload
pen
follow
pc
calv
weigh
blood
sampl
collect
via
jugular
venipuntur
evacu
tube
vacutain
bd
inc
franklin
lake
nj
determin
total
differenti
peripher
blood
leukocyt
pbl
mg
tube
ref
bvdv
antibodi
titer
sst
tube
ref
stratifi
bw
assign
randomli
treatment
pccon
pcpi
coincid
pc
group
calv
assembl
region
auction
market
deliv
ru
h
pc
arriv
upon
arriv
ru
calv
held
singl
isol
unload
pen
ad
libitum
access
hay
water
trial
initi
calv
weigh
identifi
uniqu
ear
identif
tag
ear
notch
test
pibvdv
statu
commerci
laboratori
cattl
stat
use
ace
method
idexx
laboratori
return
isol
unload
pen
one
anim
block
identifi
pibvdv
remov
studi
quarantin
cattl
receiv
vaccin
process
regimen
describ
pc
origin
ranch
therefor
first
known
vaccin
process
occur
rather
previous
origin
ranch
pc
calv
revaccin
pentaval
mlv
respiratori
vaccin
express
bivi
occur
addit
administr
clostridi
bacterintoxoid
alpha
bivi
addit
bull
calv
castrat
surgic
stratifi
gender
bw
calv
assign
randomli
treatment
amcon
ampi
upon
trial
initi
cattl
move
randomli
assign
pen
provid
kgd
asf
basi
receiv
supplement
tabl
cp
dm
basi
ad
libitum
access
bermudagrass
hay
cp
ndf
adf
dm
basi
water
supplement
offer
stepwis
increas
maximum
kgd
pen
complet
consum
supplement
offer
consecut
day
bw
measur
obtain
individu
without
withhold
feed
water
consecut
day
begin
end
receiv
trial
use
stanchion
equip
electron
load
cell
determin
overal
differ
gain
perform
determin
interim
differ
bw
gain
perform
individu
bw
record
interv
trial
furthermor
calv
blood
sampl
right
jugular
vein
determin
interim
total
differenti
pbl
bvdv
type
antibodi
titer
anticoagul
whole
blood
collect
anim
edta
tube
kept
refriger
analyz
within
h
determin
percentag
concentr
n
total
differenti
lymphocyt
neutrophil
monocyt
eosinophil
basophil
pbl
platelet
red
blood
cell
hemoglobin
hematocrit
autom
hemacytomet
celldyn
system
abbott
laboratori
abbott
park
il
standard
analysi
bovin
blood
blood
collect
anim
plain
evacu
tube
centrifug
g
min
serum
decant
duplic
aliquot
store
frozen
c
subsequ
individu
sampl
aliquot
select
randomli
treatment
pen
ship
ice
via
overnight
parcel
servic
iowa
state
univers
veterinari
diagnost
laboratori
isuvdl
ame
ia
determin
serum
neutral
antibodi
titer
concentr
seroconvers
bvdv
type
singer
strain
use
viru
neutral
vn
assay
second
set
serum
aliquot
sampl
pool
within
day
treatment
pen
ship
ice
via
overnight
parcel
servic
texa
veterinari
medic
diagnost
laboratori
amarillo
tvmdl
amarillo
tx
determin
serum
neutral
antibodi
titer
concentr
bvdv
type
nadl
strain
tgac
strain
strain
use
vn
assay
titer
report
reciproc
greatest
dilut
serum
provid
complet
protect
cell
individu
titer
analysi
isuvdl
least
dilut
serum
test
wherea
greatest
dilut
test
serum
provid
complet
protect
level
report
consid
seroneg
bvdv
type
sampl
report
serum
neutral
valu
consid
seroposit
bvdv
type
pool
titer
analysi
tvmdl
least
dilut
serum
test
wherea
greatest
dilut
test
titer
analys
report
valu
transform
statist
analysi
differ
among
bvdv
subgenotyp
titer
respons
evalu
provid
fieldstudi
insight
antigen
differ
bvdv
genotyp
strain
test
mlv
respiratori
vaccin
exposur
pibvdv
type
pen
mate
two
group
anim
previous
earnotch
test
commerci
laboratori
cattl
stat
identifi
posit
pibvdv
accord
ace
method
acquir
stocker
cattl
oper
washington
counti
ok
use
pibvdv
exposur
sourc
upon
arriv
ru
pibvdv
anim
earnotch
second
time
sampl
ship
via
overnight
parcel
servic
differ
laboratori
oklahoma
anim
diseas
diagnost
lab
stillwat
ok
usda
ar
nation
anim
diseas
center
nadc
ame
ia
rapid
affirm
posit
pibvdv
statu
use
ace
procedur
group
n
assembl
trial
initi
use
shipment
block
wherea
group
n
assembl
begin
block
use
block
trial
depend
block
pibvdv
challeng
calv
assign
randomli
pidesign
pen
draw
pen
assign
number
appropri
number
pibvdv
calv
assembl
group
allow
avail
altern
origin
design
pibvdv
anim
die
pibvdv
calf
die
trial
group
n
group
n
replac
immedi
confirm
piposit
altern
addit
anticoagul
blood
collect
pibvdv
challeng
anim
ship
ice
via
overnight
parcel
servic
nadc
subsequ
differenti
bvdv
subgenotyp
strain
use
method
viru
isol
buffi
coat
cell
phylogenet
analysi
previous
describ
ridpath
et
al
subgenotyp
strain
piposit
altern
group
determin
therefor
unknown
pibvdv
calv
acquir
use
exposur
sourc
current
studi
subgenotyp
confirm
identifi
subgenotyp
one
pibvdv
anim
group
identifi
subgenotyp
pen
anim
assign
remov
statist
analys
import
note
bvdv
type
subgenotyp
strain
pibvdv
calv
use
experi
identifi
predomin
bvdv
subgenotyp
strain
isol
cattl
us
fulton
et
al
ridpath
et
al
howev
pentaval
mlv
respiratori
vaccin
use
studi
contain
bvdv
type
strain
current
commerci
licens
mlv
respiratori
vaccin
us
contain
bvdv
isol
avoid
unwant
pibvdv
fencelin
water
sourc
contact
con
mixedgrass
receiv
pen
arrang
spatial
treatment
alloc
figur
spatial
pen
arrang
use
current
studi
may
contribut
confound
effect
locat
within
ru
facil
howev
determin
potenti
confound
effect
fencelin
water
sourc
contact
pi
con
signific
pen
measur
contain
feed
bunklin
fencelin
water
sourc
share
adjac
pen
treatment
furthermor
treatment
pen
configur
unlik
treatment
pen
separ
either
drover
feed
alley
within
manag
group
pc
calv
stratifi
gender
bw
assign
randomli
pi
con
pen
depend
block
calvespen
result
total
experiment
unit
pen
replic
amcon
ampi
pccon
pcpi
respect
pi
treatment
pibvdv
type
challeng
anim
assign
randomli
pidesign
treatment
pen
pen
within
block
equival
number
cattl
weigh
brd
evalu
procedur
con
treatment
evalu
first
follow
pi
treatment
avoid
unwant
con
contact
pi
challeng
anim
experiment
cattl
pi
treatment
reduc
potenti
exposur
fomit
contamin
bodi
fluid
fecal
materi
contain
bvdv
spatial
treatment
arrang
necess
evalu
con
follow
pi
morbid
investig
blind
experiment
treatment
calv
observ
daili
clinic
sign
brd
depress
nasal
discharg
ocular
discharg
cough
gaunt
appear
inappet
experi
station
personnel
combin
experi
evalu
cattl
brd
visual
sign
exist
calv
brought
restrain
chute
weigh
rectal
temperatur
record
via
digit
thermomet
gla
agricultur
electron
san
lui
obispo
ca
readabl
rectal
temperatur
cattl
consid
morbid
administ
antibiot
therapi
enrofloxacin
baytril
bayer
anim
health
shawne
mission
ks
dosag
rate
mgkg
bw
immedi
return
studi
pen
posttreat
interv
pti
implement
administr
enrofloxacin
second
temperatur
record
upon
expir
initi
antibiot
pti
second
temperatur
second
antibiot
treatment
florfenicol
nuflor
scheringplough
anim
health
summit
nj
administ
dosag
rate
mgkg
bw
pti
also
implement
cattl
administ
florfenicol
rectal
temperatur
evalu
upon
expir
second
antibiot
pti
temperatur
third
final
antibiot
treatment
ceftiofur
hcl
excenel
rtu
pfizer
anim
health
new
york
ny
administ
dosag
rate
mgkg
bw
repeat
consecut
day
initi
inject
ceftiofur
hcl
time
rectal
temperatur
anim
left
untreat
return
immedi
studi
pen
subsequ
sign
warrant
reexamin
treatment
data
record
individu
anim
includ
treatment
date
rectal
temperatur
amount
ml
antibiot
administ
averag
antibiot
treatment
cost
calcul
use
fix
cost
enrofloxacin
florfenicol
ceftiofur
hcl
anim
classifi
chronic
ill
antibiot
treatment
administ
coupl
kg
adg
entir
trial
brd
relaps
rate
determin
divid
number
calv
experiment
treatment
treat
second
antibiot
total
number
calv
experiment
treatment
treat
brd
perform
morbid
data
analyz
random
complet
block
design
use
mix
procedur
sa
inst
inc
cari
nc
pen
consid
experiment
unit
class
statement
includ
block
date
arriv
treatment
replic
block
consid
random
effect
statist
model
singl
degre
freedom
orthogon
contrast
evalu
effect
manag
pc
exposur
pi
con
interact
use
interact
signific
p
treatment
mean
separ
ttest
use
pdiff
option
sa
main
effect
manag
exposur
pvalu
consid
statist
signific
bvdv
titer
leukocyt
repeat
measur
data
model
includ
treatment
day
treatment
day
block
treatment
day
pen
use
class
statement
block
random
variabl
pen
within
block
subject
repeat
statement
day
covari
model
structur
use
ar
contrast
repeat
measur
data
includ
manag
exposur
manag
exposur
interact
pearson
correl
coeffici
brd
morbid
bvdv
titer
concentr
gener
use
corr
procedur
sa
treatment
interact
p
observ
anim
perform
tabl
main
effect
manag
frequent
observ
growth
perform
pc
steer
greater
p
adg
compar
calv
vs
kgd
vs
kgd
vs
kgd
indic
wean
manag
intend
improv
diseas
resist
mitig
physiolog
stress
beef
calv
result
greater
bw
gain
perform
stocker
receiv
period
howev
commingl
addit
stressor
result
market
process
experienc
pc
consid
observ
improv
perform
precondit
calv
agreement
report
literatur
step
et
al
compar
health
perform
beef
calv
singlesourc
ranch
use
precondit
manag
strategi
ranch
calv
procur
assembl
multipl
auction
market
market
commingl
group
comm
contain
portion
ranch
market
origin
cattl
studi
regardless
wean
vaccin
statu
calv
origin
ranch
tend
greater
adg
comm
market
calv
receiv
period
trial
conduct
clark
et
al
lowrisk
precondit
calv
greater
adg
finish
period
highrisk
auction
market
calv
unknown
histori
howev
differ
perform
observ
receiv
period
seeger
et
al
observ
auction
market
steer
unknown
origin
health
histori
gain
kgd
less
finish
period
wean
beef
calv
receiv
health
protocol
origin
ranch
market
pritchard
mendez
suggest
nonprecondit
calv
may
fulli
compens
initi
perform
loss
end
feed
period
howev
nonprecondit
cattl
use
experi
maintain
singlesourc
subject
stressor
associ
auction
market
system
overal
adg
affect
p
presenc
pibvdv
pen
mate
howev
final
interim
period
pibvdv
exposur
result
kgd
decreas
p
adg
perform
loss
observ
agre
find
hessman
et
al
cattl
directli
expos
pibvdv
anim
gain
kgd
less
bw
nonexpos
cattl
feedlot
starter
period
elam
et
al
observ
tendenc
pibvdvexpos
cattl
gain
less
bw
overal
adg
affect
pibvdv
exposur
studi
perform
affect
p
pibvdv
exposur
trial
nevertheless
initi
week
studi
pibvdv
anim
may
unintent
serv
trainer
anim
previous
acclim
ru
seri
trial
loerch
fluharti
observ
increas
eat
behavior
variabl
adg
newli
receiv
calv
trainer
cow
present
pen
initi
overal
differ
growth
undetect
trial
anoth
consider
shortterm
exposur
lowvirul
bvdv
strain
pi
pen
mate
could
imit
unattenu
autogen
vaccin
result
undetect
small
perform
differ
initi
week
pibvdv
exposur
howev
pibvdv
exposur
continu
progress
effect
host
immun
activ
inflamm
may
result
perform
loss
observ
repeat
immun
stimul
result
nutrient
preferenti
use
immun
homeostat
pathway
rather
tissu
deposit
klase
korver
spurlock
furthermor
catabol
effect
proinflammatori
cytokin
stimul
continu
pibvdv
exposur
may
inhibit
growth
johnson
studi
therefor
perform
consequ
newli
receiv
cohort
expos
pibvdv
pen
mate
may
delay
sever
week
immunomodul
result
pibvdv
exposur
potenti
effect
growth
progress
altern
immunomodulatori
effect
pibvdv
exposur
may
indirect
effect
growth
via
increas
suscept
cohort
complic
infect
virus
bacteria
involv
brd
therebi
decreas
health
perform
gardner
et
al
nevertheless
adg
result
suggest
may
signific
metabol
cost
associ
continu
exposur
pi
anim
shed
lowvirul
bvdv
strain
perform
loss
may
immedi
rather
sever
week
subsequ
nutrient
use
humor
cellmedi
immun
catabol
effect
proinflammatori
cytokin
stimul
associ
repeat
bvdv
exposur
presum
reach
threshold
effect
growth
perform
bw
measur
record
beyond
receiv
period
durat
perform
loss
whether
compensatori
gain
finish
phase
unknown
warrant
investig
publish
research
evalu
pibvdv
exposur
effect
perform
limit
conflict
therefor
addit
studi
care
consider
manag
health
histori
experiment
cattl
differ
virul
subgenotyp
strain
pibvdv
challeng
anim
epidemiolog
factor
requir
determin
effect
pibvdv
exposur
perform
throughout
variou
stage
beef
product
system
furthermor
better
understand
metabol
respons
physiolog
alter
immunomodul
pibvdv
exposur
need
pretrial
precondit
phase
pc
steer
requir
antibiot
treatment
origin
ranch
data
shown
total
brd
morbid
rate
markedli
greater
p
compar
pc
calv
respect
requir
treatment
clinic
brd
tabl
furthermor
greater
percentag
calv
requir
treatment
second
p
third
p
antibiot
observ
manag
effect
brd
morbid
similar
clark
et
al
brd
morbid
rate
steer
consid
either
high
lowrisk
develop
sign
brd
respect
studi
macartney
et
al
seeger
et
al
report
calv
unknown
health
histori
greater
morbid
compar
administ
health
protocol
market
similarli
roeber
et
al
observ
cattl
origin
precondit
program
fewer
hospit
visit
cattl
origin
auction
market
step
et
al
report
morbid
ranchorigin
auctionmarket
calv
within
ranchorigin
calv
wean
ship
directli
feedlot
greater
morbid
compar
kept
ranch
howev
vaccin
mlv
respiratori
vaccin
wean
reduc
morbid
receiv
period
among
treatment
kept
ranch
observ
may
suggest
wean
manag
profound
effect
reduc
subsequ
morbid
administr
mlv
respiratori
vaccin
antibiot
treatment
cost
receiv
period
increas
p
compar
pc
moreov
percentag
chronic
ill
cattl
greater
p
differ
observ
health
variabl
among
cattl
manag
sourc
current
studi
support
evid
recent
research
would
suggest
clearli
singlesourc
pc
calv
fewer
brdrelat
health
problem
improv
anim
wellb
reduc
antibiot
usag
compar
commingl
calv
unknown
manag
health
histori
nevertheless
improv
health
paramet
observ
pc
vs
current
studi
attribut
sole
precondit
manag
pc
calv
commingl
subject
auction
market
system
taylor
et
al
total
brd
morbid
rate
affect
p
pibvdv
exposur
howev
treatment
third
antibiot
occur
often
p
pibvdvexpos
cohort
although
treatment
interact
signific
p
number
cattl
treat
thrice
numer
differ
pronounc
within
calv
ampi
calv
treat
thrice
amcon
wherea
pcpi
calv
treat
thrice
pccon
treatment
interact
p
observ
percentag
chronic
ill
anim
ampi
greatest
number
chronic
ill
calv
amcon
intermedi
pccon
pcpi
least
respect
observ
suggest
wean
manag
exposur
pibvdv
pen
mate
affect
health
addit
percentag
chronic
ill
greatest
ampi
differ
among
pccon
pcpi
numer
statist
differ
p
observ
pibvdvexpos
cohort
increas
antibiot
treatment
cost
averag
pi
con
respect
within
cohort
ampi
antibiot
treatment
cost
amcon
numer
increas
similar
estim
pibvdv
test
cost
includ
next
day
parcel
servic
fee
observ
among
ampi
amcon
agre
anoth
studi
use
highrisk
calv
unknown
histori
hessman
et
al
overal
morbid
differ
direct
piexpos
unexpos
group
howev
percentag
first
relaps
chronic
ill
fatal
greater
direct
piexpos
group
trial
treatment
costanim
statist
differ
p
numer
increas
observ
direct
piexpos
group
loneragan
et
al
determin
cattl
expos
pibvdv
anim
greater
risk
initi
brd
treatment
clinic
ill
cattl
pibvdv
anim
pen
administ
antibiot
treatment
nonexpos
pen
vs
convers
booker
et
al
observ
differ
brd
health
among
pi
nonpiexpos
pen
wherea
oconn
et
al
observ
diseas
preval
reduc
pen
contain
lowrisk
singlesourc
cattl
pibvdv
calf
present
elam
et
al
use
lowrisk
precondit
heifer
also
receiv
antibiot
metaphylaxi
onarriv
report
differ
health
either
short
h
longterm
durat
studi
exposur
pibvdv
pen
mate
observ
health
differ
piexpos
cohort
use
lowrisk
precondit
heifer
would
agre
observ
health
differ
pccon
pcpi
treatment
feedlot
studi
use
auctionderiv
cattl
steven
et
al
morbid
increas
pen
shortterm
exposur
pibvdv
convers
subsequ
studi
conduct
feedlot
facil
steven
et
al
pi
anim
remov
rapidli
overal
morbid
mortal
consider
less
initi
brd
treatment
reduc
piexpos
pen
rational
conflict
anim
health
observ
pibvdvexpos
cohort
report
literatur
explain
previou
manag
health
histori
cattl
use
within
among
scientif
experi
vari
thu
suscept
experiment
calv
pibvdv
exposur
differ
virul
bvdv
strain
transmit
pi
challeng
anim
addit
exposur
rate
durat
pibvdv
challeng
differ
among
experi
variat
complex
popul
dynam
diseas
transmiss
protect
given
experiment
pen
treatment
group
exist
stokka
observ
chronic
ill
cattl
preval
ampi
less
pronounc
anim
health
differ
observ
among
pcpi
pccon
treatment
suggest
previou
manag
vaccin
bvdv
respiratori
pathogen
may
afford
degre
cohort
toler
pibvdv
pen
mate
extent
pibvdv
exposur
affect
econom
import
trait
relat
brd
morbid
current
model
affect
previou
manag
health
histori
newli
receiv
calv
suggest
factor
addit
therefor
decis
invest
pibvdv
control
program
stocker
feedlot
product
system
base
partli
upon
perceiv
brd
risk
level
group
newli
receiv
calv
upon
arriv
ru
bvdv
type
singer
strain
antibodi
titer
markedli
greater
treatment
day
p
figur
pc
percentag
seroposit
pc
vs
differ
antibodi
titer
bvdv
type
suggest
calv
rel
pc
calv
greater
humor
immun
protect
bvdv
challeng
furthermor
greater
serum
antibodi
titer
bvdv
type
neg
correl
p
correl
coeffici
subsequ
clinic
brd
morbid
trial
previou
serolog
data
martin
et
al
oconnor
et
al
also
indic
greater
serum
antibodi
titer
bvdv
upon
arriv
feedlot
correspond
subsequ
reduct
risk
clinic
brd
bolin
ridpath
observ
calv
greater
titer
level
passiv
acquir
viral
neutral
antibodi
serum
reduc
durat
sever
clinic
diseas
intranas
bvdv
challeng
anoth
trial
fulton
et
al
vaccin
dose
mlv
respiratori
vaccin
contain
bvdv
type
isol
provid
protect
viremia
calv
expos
pibvdv
type
challeng
anim
observ
period
howev
also
suggest
decreas
serum
concentr
preexist
antibodi
particularli
heterolog
subgenotyp
strain
shed
pi
challeng
anim
may
suffici
provid
complet
protect
fulton
et
al
bvdv
type
titer
concentr
similar
treatment
howev
averag
incid
first
second
third
brd
treatment
episod
respect
fewer
brd
episod
occur
consid
receiv
ident
vaccin
process
procedur
pc
time
administr
differ
suggest
mlv
respiratori
vaccin
marketassoci
stress
pathogen
exposur
critic
achiev
suffici
antibodi
titer
concentr
initi
receiv
brd
frequent
furthermor
observ
lend
evid
onarriv
mlv
respiratori
vaccin
recent
vaccin
pc
calv
may
redund
pc
steer
studi
revaccin
yet
seroposit
bvdv
type
brd
morbid
pc
calv
receiv
period
low
similar
result
individu
titer
analysi
manag
effect
p
observ
pool
bvdv
type
nadl
strain
figur
bvdv
type
tgac
strain
figur
bvdv
type
strain
figur
titer
antibodi
titer
concentr
greater
pc
compar
continu
exposur
pibvdv
type
pen
mate
main
effect
exposur
observ
bvdv
type
p
p
p
titer
concentr
howev
treatment
day
interact
observ
p
bvdv
subgenotyp
titer
analyz
log
titer
concentr
bvdv
type
increas
log
respect
pcpi
vs
pccon
therefor
continu
exposur
pibvdv
pen
mate
stimul
humor
immun
respons
pc
cohort
magnitud
increas
greatest
homolog
bvdv
strain
type
burciagarobl
et
al
observ
increas
antibodi
titer
bvdv
type
tgac
strain
type
singer
strain
strain
steer
expos
pibvdv
type
challeng
anim
h
studi
compar
viru
neutral
result
bvdv
strain
belong
differ
subgenotyp
ridpath
et
al
report
ratio
viru
crossneutr
among
bvdv
type
similar
increas
titer
concentr
piexposur
evid
p
ampi
howev
mlv
respiratori
vaccin
administ
calv
contain
bvdv
type
isol
like
confound
antibodi
titer
respons
pibvdv
type
exposur
nevertheless
increas
serum
antibodi
titer
associ
pibvdvexpos
cohort
may
greater
homogen
subgenotyp
strain
shed
pibvdv
pen
mate
effect
manag
p
tabl
day
p
observ
total
pbl
concentr
total
pbl
averag
pc
treatment
respect
total
pbl
concentr
increas
overal
time
observ
total
pbl
greater
brd
morbid
least
pc
suggest
total
pbl
concentr
may
correspond
stress
clinic
brd
howev
clarif
potenti
stressdiseas
interact
total
pbl
concentr
need
treatment
day
interact
observ
percentag
neutrophil
p
percentag
lymphocyt
p
lymphocyt
count
p
neutrophil
lymphocyt
ratio
p
figur
neutrophil
increas
pc
calv
manag
effect
p
wherea
lymphocyt
count
percentag
increas
pc
studi
progress
manag
effect
p
result
overal
neutrophil
lymphocyt
ratio
n
l
greater
p
calv
trial
progress
n
l
increas
decreas
pc
treatment
day
p
studi
kegley
et
al
ishizaki
kariya
report
transient
increas
n
l
cattl
experienc
transport
stress
howev
addit
effect
addit
stressor
also
shown
increas
n
l
wean
hickey
et
al
commingl
mcglone
et
al
may
explain
extend
durat
increas
n
l
observ
calv
studi
respiratori
pathogen
also
modul
total
differenti
pbl
cattl
challeng
bvdv
manheimia
haemolytica
report
affect
sever
pbl
concentr
burciagarobl
et
al
treatment
day
interact
observ
concentr
red
blood
cell
p
hemoglobin
p
platelet
p
percentag
hematocrit
p
figur
tendenc
exposur
effect
occur
hemoglobin
p
hematocrit
p
mean
valu
greater
piexpos
cohort
manag
effect
p
observ
platelet
concentr
greater
platelet
may
indic
presenc
increas
inflamm
stimul
cellmedi
immun
respons
platelet
abund
sourc
signal
molecul
bcell
activ
sowa
et
al
observ
greater
clinic
brd
timefram
clinic
morbid
occur
support
associ
among
platelet
level
cellmedi
immun
stimul
major
clinic
brd
occur
correl
peak
platelet
concentr
observ
research
need
understand
effect
stress
pibvdv
exposur
pbl
platelet
concentr
determin
valid
either
biomark
stress
diseas
cattl
conclus
health
manag
histori
particular
pen
group
cattl
whether
expos
pibvdv
pen
mate
may
import
aspect
affect
durat
sever
clinic
brd
chronic
ill
cattl
greatest
ampi
variat
health
manag
histori
experiment
anim
among
within
studi
may
explain
conflict
health
perform
result
pibvdv
exposur
publish
literatur
may
confound
result
unaccount
addit
research
consid
issu
need
determin
pibvdv
test
remov
newli
receiv
calv
econom
justifi
differ
beef
product
system
furthermor
bw
gain
perform
reduc
piexpos
cohort
suggest
metabol
cost
associ
immunomodul
exposur
pibvdv
pen
mate
howev
durat
perform
loss
whether
compensatori
bw
gain
occur
finish
phase
unknown
studi
end
result
suggest
minim
effect
health
singlesourc
pc
steer
expos
pibvdv
pen
mate
receiv
period
justifi
cost
incur
labor
ship
laboratori
test
earnotch
sampl
remov
piposit
anim
nevertheless
highrisk
commingl
cattl
variou
brd
pathogen
experi
greater
clinic
brd
morbid
may
warrant
test
remov
pibvdv
anim
addit
effect
manag
piexposur
evid
percentag
chronic
ill
support
research
random
control
trial
need
better
understand
health
perform
econom
consequ
pibvdv
exposur
cohort
differ
wean
manag
system
